Tuesday, November 08, 2022 7:24:18 PM
HyGro,
The MIA approval (commercial scale manufacturing UK) must happen BEFORE MAA approval. FDA also requires proof of ability to ramp up to expected demand levels before any BLA can be approved and that proof can be submitted during the course of a rolling BLA application especially if one method is being exchanged for another during the submission period leading to a completed BLA.
The building and use permit at the Memphis site for Cognate/CRL has publicly established plans for a massive expansion next year in line with expectations for an approval of a new, high demand cell based product. Commercial scale readiness has been moving at a rapid pace ever since the time that the company would have been unblinded which is also the time when loans were granted to NWBO for funding of ongoing operations. In days to months what is obvious to thousands will be obvious to millions which means no stopping NWBO then. Best wishes.
The MIA approval (commercial scale manufacturing UK) must happen BEFORE MAA approval. FDA also requires proof of ability to ramp up to expected demand levels before any BLA can be approved and that proof can be submitted during the course of a rolling BLA application especially if one method is being exchanged for another during the submission period leading to a completed BLA.
The building and use permit at the Memphis site for Cognate/CRL has publicly established plans for a massive expansion next year in line with expectations for an approval of a new, high demand cell based product. Commercial scale readiness has been moving at a rapid pace ever since the time that the company would have been unblinded which is also the time when loans were granted to NWBO for funding of ongoing operations. In days to months what is obvious to thousands will be obvious to millions which means no stopping NWBO then. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
